Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Heterocyclic compound >  Pyridine compound >  Dihydropyridine >  ARRY-424704, ARRY-704

ARRY-424704, ARRY-704

Basic information Safety Supplier Related

ARRY-424704, ARRY-704 Basic information

Product Name:
ARRY-424704, ARRY-704
Synonyms:
  • ARRY-424704, ARRY-704
  • AZD8330
  • 2-(2-Fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
  • ARRY424704
  • ARRY-424704
  • ARRY704
  • ARRY-704
  • AZD8330/ARRY-424704/arry-704/AZD8330/AZD-8330
CAS:
869357-68-6
MF:
C16H17FIN3O4
MW:
461.23
EINECS:
642-441-7
Product Categories:
  • Inhibitors
  • MAPK
Mol File:
869357-68-6.mol
More
Less

ARRY-424704, ARRY-704 Chemical Properties

Density 
1.732
storage temp. 
Store at -20°C
solubility 
≥23.05 mg/mL in DMSO; insoluble in H2O; ≥46.1 mg/mL in EtOH
form 
solid
pka
14.31±0.10(Predicted)
color 
Off-white to pink
More
Less

Safety Information

HS Code 
2933998090
More
Less

ARRY-424704, ARRY-704 Usage And Synthesis

Description

AZD 8330 is a selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM). It blocks phosphorylation of ERK1/2 and inhibits proliferation of certain cancer cells. AZD 8330 is orally bioavailable, inhibits ERK phosphorylation in vivo, and reduces tumor growth in a Calu-6 nude rat xenograft model.

Uses

AZD8330 is an orally active and selective MEK inhibitor.

Definition

ChEBI: 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide is a pyridinecarboxamide. It is functionally related to a nicotinamide.

in vivo

In tumour xenograft models, AZD8330 demonstrates dose-dependent tumour growth inhibition of approximately 90% at tolerated doses (1.0 mg/kg once daily [OD])[1].

target

ERK phosphorylation

IC 50

MEK1: 7 nM (IC50); MEK2: 7 nM (IC50)

References

1. feng k, wang c, zhou h, yang j, dong l, zhou k, et al. [effect of erk1/2 inhibitor azd8330 on human burkitt's lymphoma cell line raji cells and its mechanism]. zhonghua xue ye xue za zhi 2015,36:148-152.2. cohen rb, aamdal s, nyakas m, cavallin m, green d, learoyd m, et al. a phase i dose-finding, safety and tolerability study of azd8330 in patients with advanced malignancies. eur j cancer 2013,49:1521-1529.

ARRY-424704, ARRY-704Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Jinan Trio PharmaTech Co., Ltd.
Tel
0531-88811783
Email
sales@trio-pharmatech.com
BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com